| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Bruce J Brew | Q61853479 |
| P2093 | author name string | Bruce James Brew | |
| Scott Lee Letendre | |||
| P2860 | cites work | Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection | Q24810504 |
| How cells respond to interferons | Q27861006 | ||
| CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia | Q28303212 | ||
| Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis | Q28646425 | ||
| Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. | Q30951456 | ||
| Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: preliminary observations | Q33228989 | ||
| Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes | Q33572329 | ||
| Neopterin: a review | Q33676500 | ||
| Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha | Q33711550 | ||
| CD14, new aspects of ligand and signal diversity | Q33887457 | ||
| HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels | Q34161535 | ||
| Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier | Q34216542 | ||
| Matrix metalloproteinases in neuroinflammation | Q34803809 | ||
| Circulating proviral HIV DNA and HIV-associated dementia | Q35012478 | ||
| Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl | Q35041797 | ||
| Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. | Q35087037 | ||
| CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42 | Q35580179 | ||
| Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains | Q35611425 | ||
| Haptoglobin polymorphism, iron metabolism and mortality in HIV infection | Q47853455 | ||
| Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia | Q47983472 | ||
| Serum and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases | Q48101098 | ||
| Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. | Q48179920 | ||
| Increased intrathecal release of soluble fractalkine in HIV-infected patients | Q48363839 | ||
| The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study | Q48440806 | ||
| Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons | Q48453173 | ||
| Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection | Q48460969 | ||
| Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction | Q48484034 | ||
| Cytokine expression in the brain during the acquired immunodeficiency syndrome | Q48496332 | ||
| TGF-beta1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death | Q48626486 | ||
| Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier | Q48755735 | ||
| Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients | Q48899585 | ||
| HIV-1 replication in the plasma and cerebrospinal fluid | Q48923755 | ||
| Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. | Q48959355 | ||
| Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. | Q50984070 | ||
| Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. | Q52018425 | ||
| A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. | Q54713181 | ||
| Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system | Q58276624 | ||
| Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma | Q58370945 | ||
| CSF soluble Fas correlates with the severity of HIV-associated dementia | Q35674446 | ||
| Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia | Q35980114 | ||
| Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome | Q36600970 | ||
| Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers | Q37015519 | ||
| CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. | Q38433078 | ||
| Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease | Q38867685 | ||
| Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort | Q39724313 | ||
| Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles | Q40260121 | ||
| Cytokine dysregulation in HIV-associated neurological disease | Q40603270 | ||
| Tumor necrosis factor receptor superfamily members and their ligands | Q40626257 | ||
| Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin | Q40933074 | ||
| Immunological Markers in the Cerebrospinal Fluid of HIV-1-Infected Children | Q41157758 | ||
| Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid | Q41262117 | ||
| Bioactive lipids in excitatory neurotransmission and neuronal plasticity | Q41338039 | ||
| Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection | Q41605507 | ||
| Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. | Q41677633 | ||
| Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources | Q41721709 | ||
| Elevated neurofilament levels in neurological diseases. | Q42450342 | ||
| Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia | Q42474669 | ||
| The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease | Q42996185 | ||
| Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases | Q43068800 | ||
| Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia | Q43586132 | ||
| Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection | Q43716030 | ||
| Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels | Q43796945 | ||
| Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease | Q44113713 | ||
| Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection | Q44200486 | ||
| Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia | Q44253971 | ||
| Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia | Q44438229 | ||
| Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia | Q44572012 | ||
| CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. | Q44795363 | ||
| Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort | Q45181283 | ||
| Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease | Q45498903 | ||
| Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. | Q45732214 | ||
| Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia | Q45747316 | ||
| Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients | Q45753927 | ||
| Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain | Q45759163 | ||
| Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group | Q45759166 | ||
| Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage | Q45764045 | ||
| Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia | Q45783247 | ||
| Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection | Q45839250 | ||
| Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid | Q45843920 | ||
| Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection | Q45849861 | ||
| Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease | Q45852279 | ||
| Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. | Q46111831 | ||
| Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia | Q46119121 | ||
| Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine | Q46455439 | ||
| Unique monocyte subset in patients with AIDS dementia | Q46631395 | ||
| Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy | Q46653138 | ||
| CSF amyloid beta42 and tau levels correlate with AIDS dementia complex | Q46794983 | ||
| The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations | Q47661196 | ||
| Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication | Q47672132 | ||
| Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy | Q47806657 | ||
| P433 | issue | 1 | |
| P921 | main subject | nervous system | Q9404 |
| biomarker | Q864574 | ||
| HIV | Q15787 | ||
| P304 | page(s) | 73-88 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | International Review of Psychiatry | Q15752216 |
| P1476 | title | Biomarkers of HIV related central nervous system disease | |
| P478 | volume | 20 |
| Q47547047 | Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment |
| Q37467991 | Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection |
| Q35902490 | Behavioral Deficits Are Accompanied by Immunological and Neurochemical Changes in a Mouse Model for Neuropsychiatric Lupus (NP-SLE). |
| Q40455681 | Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. |
| Q33614467 | Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals |
| Q40692788 | CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF |
| Q26801033 | Cerebrospinal fluid analysis in the HIV infection and compartmentalization of HIV in the central nervous system |
| Q38154123 | Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers |
| Q35037015 | Controversies in HIV-associated neurocognitive disorders |
| Q41551768 | Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). |
| Q27025018 | HIV and aging: effects on the central nervous system |
| Q38461834 | HIV-associated neurocognitive disorders |
| Q35702700 | Human immunodeficiency virus-associated dementia: a link between accumulation of viral proteins and neuronal degeneration. |
| Q26779435 | Impact of cocaine abuse on HIV pathogenesis |
| Q38767396 | Interventions for Neurocognitive Dysfunction |
| Q53691998 | Is Tobacco Use Associated with Neurocognitive Dysfunction in Individuals with HIV? |
| Q38071699 | Is specific HIV eradication from the brain possible or needed? |
| Q35997428 | Methamphetamine abuse affects gene expression in brain-derived microglia of SIV-infected macaques to enhance inflammation and promote virus targets |
| Q34243885 | Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men |
| Q36060674 | Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection |
| Q38887687 | Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation |
| Q35175447 | Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection |
| Q40314419 | Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection |
| Q97524620 | Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders |
| Q34162407 | PrPC, the Cellular Isoform of the Human Prion Protein, Is a Novel Biomarker of HIV-Associated Neurocognitive Impairment and Mediates Neuroinflammation |
| Q36667153 | Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration |
| Q35883306 | Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. |
| Q37362071 | Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? |
| Q40437527 | Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions. |
| Q37372353 | Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals |
Search more.